BACKGROUND: Stroke-associated infections occur frequently and are associated with unfavorable outcome. Previous cohort studies suggest a protective effect of beta-blockers (BBs) against infections. A sympathetic drive may increase immune suppression and infections. AIM: This study is aimed at investigating the association between BB treatment at baseline and post-stroke infection in the Preventive Antibiotics in Stroke Study (PASS), a prospective clinical trial. METHODS: We performed an exploratory analysis in PASS, 2,538 patients with acute phase of stroke (24 h after onset) were randomized to ceftriaxone (intravenous, 2 g per day for 4 days) in addition to stroke unit care, or standard stroke unit care without preventive antibiotic treatment. All clinical data, including use of BBs, was prospectively collected. Infection was diagnosed by the treating physician, and independently by an expert panel blinded for all other data. Multivariable analysis was performed to investigate the relation between BB treatment and infection rate. RESULTS: Infection, as defined by the physician, occurred in 348 of 2,538 patients (14%). Multivariable analysis showed that the use of BBs at baseline was associated with the development of infection during clinical course (adjusted OR (aOR) 1.61, 95% CI 1.19-2.18; p < 0.01). BB use at baseline was also associated with the development of pneumonia (aOR 1.56, 95% CI 1.05-2.30; p = 0.03). Baseline BB use was not associated with mortality (aOR 1.14, 95% CI 0.84-1.53; p = 0.41) or unfavorable outcome at 3 months (aOR 1.10, 95% CI 0.89-1.35; p = 0.39). CONCLUSIONS: Patients treated with BBs prior to stroke have a higher rate of infection and pneumonia.
BACKGROUND: Stroke-associated infections occur frequently and are associated with unfavorable outcome. Previous cohort studies suggest a protective effect of beta-blockers (BBs) against infections. A sympathetic drive may increase immune suppression and infections. AIM: This study is aimed at investigating the association between BB treatment at baseline and post-stroke infection in the Preventive Antibiotics in Stroke Study (PASS), a prospective clinical trial. METHODS: We performed an exploratory analysis in PASS, 2,538 patients with acute phase of stroke (24 h after onset) were randomized to ceftriaxone (intravenous, 2 g per day for 4 days) in addition to stroke unit care, or standard stroke unit care without preventive antibiotic treatment. All clinical data, including use of BBs, was prospectively collected. Infection was diagnosed by the treating physician, and independently by an expert panel blinded for all other data. Multivariable analysis was performed to investigate the relation between BB treatment and infection rate. RESULTS: Infection, as defined by the physician, occurred in 348 of 2,538 patients (14%). Multivariable analysis showed that the use of BBs at baseline was associated with the development of infection during clinical course (adjusted OR (aOR) 1.61, 95% CI 1.19-2.18; p < 0.01). BB use at baseline was also associated with the development of pneumonia (aOR 1.56, 95% CI 1.05-2.30; p = 0.03). Baseline BB use was not associated with mortality (aOR 1.14, 95% CI 0.84-1.53; p = 0.41) or unfavorable outcome at 3 months (aOR 1.10, 95% CI 0.89-1.35; p = 0.39). CONCLUSIONS: Patients treated with BBs prior to stroke have a higher rate of infection and pneumonia.
Authors: Ángel Chamorro; Andreas Meisel; Anna M Planas; Xabier Urra; Diederik van de Beek; Roland Veltkamp Journal: Nat Rev Neurol Date: 2012-06-05 Impact factor: 42.937
Authors: Craig J Smith; Amit K Kishore; Andy Vail; Angel Chamorro; Javier Garau; Stephen J Hopkins; Mario Di Napoli; Lalit Kalra; Peter Langhorne; Joan Montaner; Christine Roffe; Anthony G Rudd; Pippa J Tyrrell; Diederik van de Beek; Mark Woodhead; Andreas Meisel Journal: Stroke Date: 2015-06-25 Impact factor: 7.914
Authors: Willeke F Westendorp; Jan-Dirk Vermeij; Elles Zock; Imke J Hooijenga; Nyika D Kruyt; Hans J L W Bosboom; Vincent I H Kwa; Martijn Weisfelt; Michel J M Remmers; Robert ten Houten; A H C M Tobien Schreuder; Sarah E Vermeer; Ewout J van Dijk; Diederik W J Dippel; Marcel G W Dijkgraaf; Lodewijk Spanjaard; Marinus Vermeulen; Tom van der Poll; Jan M Prins; Frederique H Vermeij; Yvo B W E M Roos; Ruud P Kleyweg; Henk Kerkhoff; Matthijs C Brouwer; Aeilko H Zwinderman; Diederik van de Beek; Paul J Nederkoorn Journal: Lancet Date: 2015-01-20 Impact factor: 79.321
Authors: Konstantin Prass; Christian Meisel; Conny Höflich; Johann Braun; Elke Halle; Tilo Wolf; Karsten Ruscher; Ilya V Victorov; Josef Priller; Ulrich Dirnagl; Hans-Dieter Volk; Andreas Meisel Journal: J Exp Med Date: 2003-08-25 Impact factor: 14.307
Authors: Ilko L Maier; Johannes C Becker; Johanna Rosemarie Leyhe; Marlena Schnieder; Daniel Behme; Marios-Nikos Psychogios; Jan Liman Journal: PLoS One Date: 2018-04-25 Impact factor: 3.240
Authors: Michelle Tørnes; David J McLernon; Max O Bachmann; Stanley D Musgrave; Elizabeth A Warburton; John F Potter; Phyo Kyaw Myint Journal: Front Neurol Date: 2019-08-06 Impact factor: 4.003